Most cited papers from Botkin Hospital

Botkin Hospital

What are the most cited papers from Botkin Hospital?

The most cited paper from Botkin Hospital is "Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma" (Jesús F. San Miguel et al., 2008), with 1,913 citations. Next come "Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study" (925) and "Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial" (804).

Published TypeFieldAccessAuthorsCitations

Showing 50 of 60 papers. Every paper with more than 31 citations is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma Jesús F. San Miguel et al. · New England Journal of Medicine Open access	27 Aug 2008	1,913
2	Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study Philippe Moreau, Halyna Pylypenko, Sebastian Grosicki et al. · The Lancet Oncology	21 Apr 2011	925
3	Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial Jesús F. San Miguel et al. · The Lancet Oncology Open access	2 Sep 2013	804
4	Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study Jong Wook Lee, Flore Sicre de Fontbrune, Lily Wong Lee Lee et al. · Blood Open access	3 Dec 2018	417
5	A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS) Ronald van Vollenhoven et al. · Annals of the Rheumatic Diseases Open access	25 Nov 2016	367
6	Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial Jan van Lunzen, Franco Maggiolo, José Ramón Arribas et al. · The Lancet Infectious Diseases	24 Oct 2011	300
7	COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus Lydia Scarfò et al. · Leukemia Open access	9 Jul 2020	276
8	Serious Fatal and Nonfatal Non-AIDS-Defining Illnesses in Europe Amanda Mocroft, PETER C. REISS, Jacek Gąsiorowski et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes Open access	10 Aug 2010	274
9	Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial María‐Victoria Mateos et al. · The Lancet Haematology Open access	23 Mar 2020	251
10	Fixed-Duration Ibrutinib-Venetoclax in Patients with Chronic Lymphocytic Leukemia and Comorbidities Arnon Philip Kater et al. · NEJM Evidence	13 May 2022	240
11	Quantitative Pathology of Inhalational Anthrax I: Quantitative Microscopic Findings Л. М. Гринберг, Faina A. Abramova, Olga V Yampolskaya et al. · Modern Pathology Open access	May 2001	234
12	Measurable Residual Disease Response and Prognosis in Treatment-Naïve Acute Myeloid Leukemia With Venetoclax and Azacitidine Keith William Pratz, Brian Andrew Jonas, Vinod A. Pullarkat et al. · Journal of Clinical Oncology Open access	15 Dec 2021	178
13	Fixed-duration ibrutinib–venetoclax versus chlorambucil–obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial Carsten Utoft Niemann et al. · The Lancet Oncology Open access	6 Nov 2023	149
14	A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older Jean‐Luc Harousseau et al. · Blood Open access	21 May 2009	147
15	Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study Meletios Athanasios Dimopoulos, María-Victoria Mateos, Paul Gerard Guy Richardson et al. · European Journal Of Haematology	28 Sep 2010	147
16	Roxadustat for anemia in patients with end-stage renal disease incident to dialysis Robert Provenzano, Evgeny V. Shutov, Л. Ф. Еремеева et al. · Nephrology Dialysis Transplantation	18 Feb 2021	136
17	Short-term antiviral activity of TMC278 – a novel NNRTI – in treatment-naive HIV-1-infected subjects Frank Detlef Goebel, Alexy Yakovlev, Anton Louis Pozniak et al. · AIDS	22 Aug 2006	131
18	Conservative kidney management and kidney supportive care: core components of integrated care for people with kidney failure Sara N. Davison et al. · Kidney International Open access	2024	93
19	Isatuximab as monotherapy and combined with dexamethasone in patients with relapsed/refractory multiple myeloma Meletios Athanasios Dimopoulos, Sara Bringhen, Pekka Anttila et al. · Blood Open access	20 Oct 2020	86
20	Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan–prednisone vs. melphalan–prednisone in the phase III VISTA trial in multiple myeloma Michel Delforge et al. · European Journal Of Haematology	3 Mar 2011	85
21	Pregnancy in Chronic Kidney Disease: Need for Higher Awareness. A Pragmatic Review Focused on What Could Be Improved in the Different CKD Stages and Phases Giorgina Barbara Piccoli, Elena Zakharova, Rossella Attini et al. · Journal of Clinical Medicine Open access	5 Nov 2018	76
22	Programmes, resources, and needs of HIV-prevention nongovernmental organizations (NGOs) in Africa, Central/Eastern Europe and Central Asia, Latin America and the Caribbean Jeffrey A. Kelly, Anton M. Somlai, Eric G. Benotsch et al. · AIDS Care Open access	8 Nov 2005	75
23	Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone Meletios Athanasios Dimopoulos et al. · Haematologica Open access	6 Aug 2015	72
24	Framework for establishing integrated kidney care programs in low- and middle-income countries Marcello A. Tonelli, Victoria Nkunu, Cherian V Varghese et al. · Kidney International Supplements Open access	19 Feb 2020	71
25	The ERA Registry Annual Report 2020: a summary Megan E Astley et al. · Clinical Kidney Journal Open access	21 Apr 2023	69
26	Women and kidney disease: reflections on World Kidney Day 2018 Giorgina Barbara Piccoli, Mona N. Alrukhaimi, Zhi-Hong Liu et al. · Kidney International Open access	19 Jan 2018	67
27	Contrast-enhanced MDCT in patients with pancreatic neuroendocrine tumours: correlation with histological findings and diagnostic performance in differentiation between tumour grades Елена Леонидовна Белоусова, Grigory Grigorievich Karmazanovsky, A. G. Kriger et al. · Clinical Radiology Open access	25 Nov 2016	65
28	In Vivo Bone Tissue Engineering Strategies: Advances and Prospects Ilya L. Tsiklin, Aleksey V. Shabunin, А. В. Колсанов et al. · Polymers Open access	8 Aug 2022	63
29	Fatal and nonfatal AIDS and non-AIDS events in HIV-1-positive individuals with high CD4 cell counts according to viral load strata Joanne Reekie, José M. Gatell, Israel Yust et al. · AIDS Open access	4 Oct 2011	61
30	Final analysis of the phase III non-inferiority COLUMBA study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma Saad Z. Usmani et al. · Haematologica Open access	31 Mar 2022	58
31	Barriers and Facilitators of HIV Care Engagement: Results of a Qualitative Study in St. Petersburg, Russia Anna Victorovna Kuznetsova, Anastasia Y. Meylakhs, Yuri A. Amirkhanian et al. · AIDS and Behavior Open access	14 Jan 2016	54
32	Clinical guidelines for diagnosis and treatment of systemic amyloidosis Lidia V. Lysenko, В. В. Рамеев, Sergey Valentinovich Moiseev et al. · Clinical pharmacology and therapy Open access	20 Feb 2020	53
33	Regional Differences in AIDS and Non-AIDS Related Mortality in HIV-Positive Individuals across Europe and Argentina: The EuroSIDA Study Joanne Reekie, Justyna Dominika Kowalska, Igor Alexandrovich Karpov et al. · PLoS ONE Open access	23 Jul 2012	53
34	Liver-related death among HIV/hepatitis C virus-co-infected individuals Daniel J. Grint, Lars Peters, Juergen Kurt Rockstroh et al. · AIDS Open access	14 Apr 2015	53
35	Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myeloma Jesús F. San Miguel et al. · Haematologica Open access	9 Jul 2015	52
36	Glomerular diseases in pregnancy: pragmatic recommendations for clinical management Fádi Fakhouri et al. · Kidney International	5 Dec 2022	50
37	37th International Symposium on Intensive Care and Emergency Medicine (part 3 of 3) And Sepsis Study Group et al. · Critical Care Open access1,024 authors	Mar 2017	50
38	Acute Kidney Injury in Pregnancy: The Need for Higher Awareness. A Pragmatic Review Focused on What Could Be Improved in the Prevention and Care of Pregnancy-Related AKI, in the Year Dedicated to Women and Kidney Diseases Giorgina Barbara Piccoli, Elena Zakharova, Rossella Attini et al. · Journal of Clinical Medicine Open access	Oct 2018	49
39	Monoclonal gammopathy of renal significance (MGRS): Real‐world data on outcomes and prognostic factors Alessandro Gozzetti et al. · American Journal of Hematology Open access	7 Apr 2022	47
40	Diphtheria Outbreak in St. Petersburg: Clinical Characteristics of 1,860 Adult Patients Asa G. Rakhmanova, Jukka Lumio, Kaj Groundstroem et al. · Scandinavian Journal of Infectious Diseases	1996	47
41	Cerebral microbleeds in early Alzheimer’s disease Tatjana Poliakova, Oleg Semenovich Levin, Alexander V. Arablinskiy et al. · Journal of Neurology	7 Jul 2016	46
42	Electrostatic binding of substituted metal phthalocyanines to enterobacterial cells: Its role in photodynamic inactivation Marina G. Strakhovskaya, Yuri N. Antonenko, Alina A. Pashkovskaya et al. · Biochemistry (Moscow)	Dec 2009	46
43	Impact of Minimal Residual Disease on Progression-Free Survival Outcomes After Fixed-Duration Ibrutinib-Venetoclax Versus Chlorambucil-Obinutuzumab in the GLOW Study Talha Munir et al. · Journal of Clinical Oncology Open access	6 Jun 2023	45
44	New Insights into the Origin of the HIV Type 1 Subtype A Epidemic in Former Soviet Union's Countries Derived from Sequence Analyses of Preepidemically Transmitted Viruses Michael M. Thomson, Elena Vázquez de Parga, Anna Vinogradova et al. · AIDS Research and Human Retroviruses	Dec 2007	44
45	Effects of a social network HIV/STD prevention intervention for MSM in Russia and Hungary Yuri A. Amirkhanian, Jeffrey A. Kelly, Judit Takács et al. · AIDS Open access	7 Jan 2015	44
46	Predictors of HIV Care Engagement, Antiretroviral Medication Adherence, and Viral Suppression Among People Living with HIV Infection in St. Petersburg, Russia Yuri A. Amirkhanian, Jeffrey A. Kelly, Wayne J. DiFranceisco et al. · AIDS and Behavior Open access	19 Dec 2016	43
47	The Burden of Comorbidities in Obstructive Sleep Apnea and the Pathophysiologic Mechanisms and Effects of CPAP Victoria Sircu, Silvia-Iaroslava Colesnic, Serghei Covanţev et al. · Clocks & Sleep Open access	19 Jun 2023	41
48	Risk of Discontinuation of Nevirapine due to Toxicities in Antiretroviral-Naive and -Experienced HIV-Infected patients with High and Low CD4 + T-cell Counts Amanda Mocroft, Schlomo Staszewski, Rainer K. Weber et al. · Antiviral Therapy Open access	Apr 2007	39
49	Multi-drug-resistant tuberculosis in HIV positive patients in Eastern Europe Frank A. Post, Daniel J. Grint, Anne Marie Werlinrud et al. · Journal of Infection	16 Nov 2013	39
50	A Russian validation study of the Coma Recovery Scale-Revised (CRS-R) Elizaveta G. Iazeva, Liudmila A. Legostaeva, А. А. Зимин et al. · Brain Injury	2 Nov 2018	38

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.